X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare SUVEN LIFE with Aventis Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUVEN LIFE vs SANOFI INDIA - Comparison Results

SANOFI INDIA 
   Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUVEN LIFE SANOFI INDIA SUVEN LIFE/
SANOFI INDIA
 
P/E (TTM) x 14.4 32.8 43.9% View Chart
P/BV x 3.4 6.6 51.9% View Chart
Dividend Yield % 0.5 1.4 37.4%  

Financials

 SUVEN LIFE   SANOFI INDIA
EQUITY SHARE DATA
    SUVEN LIFE
Mar-17
SANOFI INDIA
Dec-16
SUVEN LIFE/
SANOFI INDIA
5-Yr Chart
Click to enlarge
High Rs2294,560 5.0%   
Low Rs1514,400 3.4%   
Sales per share (Unadj.) Rs42.71,028.5 4.2%  
Earnings per share (Unadj.) Rs6.9129.0 5.3%  
Cash flow per share (Unadj.) Rs8.5186.0 4.6%  
Dividends per share (Unadj.) Rs1.0068.00 1.5%  
Dividend yield (eoy) %0.51.5 34.7%  
Book value per share (Unadj.) Rs52.4753.6 7.0%  
Shares outstanding (eoy) m127.2823.03 552.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.44.4 102.0%   
Avg P/E ratio x27.734.7 79.8%  
P/CF ratio (eoy) x22.224.1 92.3%  
Price / Book Value ratio x3.65.9 60.9%  
Dividend payout %14.652.7 27.7%   
Avg Mkt Cap Rs m24,158103,174 23.4%   
No. of employees `0001.03.6 28.0%   
Total wages/salary Rs m5223,592 14.5%   
Avg. sales/employee Rs Th5,349.76,537.7 81.8%   
Avg. wages/employee Rs Th513.5991.4 51.8%   
Avg. net profit/employee Rs Th858.1819.8 104.7%   
INCOME DATA
Net Sales Rs m5,43523,686 22.9%  
Other income Rs m211708 29.8%   
Total revenues Rs m5,64624,394 23.1%   
Gross profit Rs m1,2915,281 24.4%  
Depreciation Rs m2141,313 16.3%   
Interest Rs m5715 378.7%   
Profit before tax Rs m1,2314,661 26.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3591,691 21.2%   
Profit after tax Rs m8722,970 29.4%  
Gross profit margin %23.722.3 106.5%  
Effective tax rate %29.236.3 80.4%   
Net profit margin %16.012.5 127.9%  
BALANCE SHEET DATA
Current assets Rs m4,91715,673 31.4%   
Current liabilities Rs m1,1866,678 17.8%   
Net working cap to sales %68.638.0 180.8%  
Current ratio x4.12.3 176.6%  
Inventory Days Days6276 81.8%  
Debtors Days Days3122 137.9%  
Net fixed assets Rs m3,1548,098 39.0%   
Share capital Rs m127230 55.3%   
"Free" reserves Rs m6,54317,088 38.3%   
Net worth Rs m6,67017,356 38.4%   
Long term debt Rs m2590-   
Total assets Rs m8,15725,400 32.1%  
Interest coverage x22.7311.7 7.3%   
Debt to equity ratio x00-  
Sales to assets ratio x0.70.9 71.5%   
Return on assets %11.411.8 96.9%  
Return on equity %13.117.1 76.4%  
Return on capital %18.626.9 69.0%  
Exports to sales %024.5 0.0%   
Imports to sales %028.0 0.0%   
Exports (fob) Rs mNA5,801 0.0%   
Imports (cif) Rs mNA6,627 0.0%   
Fx inflow Rs m4,9967,145 69.9%   
Fx outflow Rs m9596,846 14.0%   
Net fx Rs m4,037299 1,350.3%   
CASH FLOW
From Operations Rs m1,0883,226 33.7%  
From Investments Rs m-3,107-1,555 199.8%  
From Financial Activity Rs m-300-1,818 16.5%  
Net Cashflow Rs m-2,319-147 1,577.3%  

Share Holding

Indian Promoters % 63.4 0.0 -  
Foreign collaborators % 0.0 60.4 -  
Indian inst/Mut Fund % 0.0 14.4 -  
FIIs % 0.0 14.6 -  
ADR/GDR % 0.0 0.0 -  
Free float % 36.5 10.5 347.6%  
Shareholders   37,287 15,184 245.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUVEN LIFE With:   FULFORD INDIA  AUROBINDO PHARMA  IPCA LABS  WOCKHARDT LTD.  SUN PHARMA  

Compare SUVEN LIFE With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens 145 Points Up; Sun Pharma Rallies on Strong Earnings(09:30 am)

Asian share markets are higher today as Japanese and Hong Kong shares show gains. The Nikkei 225 is flat while the Hang Seng is up 0.7%.

Related Views on News

Suven Lifesciences: Profits Decline due to Higher tax outgo in the quarter (Quarterly Results Update - Detailed)

Sep 22, 2017

Muted growth in CRAMS segment continues to impact topline.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

My Top Five Stocks After the Karnataka Elections(The 5 Minute Wrapup)

May 16, 2018

The markets seem confused. They're neither going up nor down. What should investors do? Consider Safe Stocks. Here's the top 5 Safe Stocks in the market today.

How A Storm Destroyed Rain Industries... And a Superb Small Cap Stock I Recommend(Profit Hunter)

May 17, 2018

A mutual fund regulation could cause small cap prices to tank - If you haven't been paying attention to your small caps - now is the time to catch the opportunities that start pouring in.

Has the Indian Home Buyer Become Smarter?(Vivek Kaul's Diary)

May 17, 2018

Home loans continue to grow, despite falling sales. What explains this phenomenon?

Beware the 5th year of the Modi Regime(The Honest Truth)

May 22, 2018

2017 was a great year for the market. You were rewarded for taking excessive risk. But Ajit Dayal believes 2018 will be different. You will be rewarded for doing the opposite. Read on to know more...

Beware of Inflated Stock Market Angels(Sector Info)

May 17, 2018

The stock of Vakrangee helps us understand why it's a bad idea to chase high-flying stocks.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SUVEN LIFE SHARE PRICE


May 28, 2018 10:49 AM

TRACK SUVEN LIFE

  • Track your investment in SUVEN LIFE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUVEN LIFE - GLENMARK PHARMA COMPARISON

COMPARE SUVEN LIFE WITH

MARKET STATS